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Introduction
Dystonia is characterized by involuntary, sus-
tained and patterned contractions of opposing 
muscles, causing twisting movements and abnor-
mal postures [Fahn et al. 1998]. It is a potentially 
disabling movement disorder, and reduced mobil-
ity, pain and a significant psychosocial impact are 
some of the consequences [Stamelou et al. 2011]. 
While dystonia can be secondary, due to for 
example structural lesions or neurodegenerative 
diseases, there is also primary dystonia, i.e. when 
dystonia (with or without tremor) is the only 
symptom, and there is no secondary cause or neu-
rodegeneration. There is no cure for primary 
dystonia, partly also because its pathophysiology 
is still incompletely understood. Therefore, treat-
ment is only symptomatic, aimed at decreasing 
the involuntary movements, correcting the abnor-
mal posture, preventing contractures, reducing 
pain and ultimately attempting to improve quality 
of life. The current cornerstones of medical 
symptomatic treatment include chemodener-
vation with botulinum toxin injections, drug 
treatment with for example anticholinergics and 
surgical treatment such as bilateral pallidal 
stimulation. In addition, patients are referred for 
various allied healthcare interventions [Delnooz 
et al. 2009]. For some of these medical interven-
tions there is good evidence, but for many sound 
scientific support is lacking [Balash and Giladi, 
2004; Albanese et al. 2011]. The clinical heteroge-
neity, the existence of various subtypes, the use of 
insufficiently validated scales to quantify the clini-
cal changes, the conduction of small and uncon-
trolled trials, and the absence of direct comparisons 
all complicate the evaluation of the therapeutic 
effect for some of the medical interventions that 
are commonly used [Jankovic, 2006].
We here attempt to provide a comprehensive 
review of medical treatment strategies in dystonia, 
with a focus on primary dystonia.
Botulinum neurotoxin
Botulinum neurotoxin (BoNT) is a toxic protein 
produced by the bacterium Clostridium botulinum. 
It selectively blocks the cholinergic innervation 
of striate and smooth muscles and exocrine 
glands [De Boer et al. 2012]. BoNT injections in 
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dystonia are given intramuscularly, often under 
electromyography (EMG) guidance, and need to 
be repeated every 3–6 months. Contraindications 
for the use of BoNT include history of neuro-
muscular disease, e.g. myasthenia gravis, Lambert–
Eaton syndrome or motor neuron disease, and a 
history of hypersensitivity to BoNT, albumin or 
saline. BoNT injections are also contraindicated 
in combination with aminoglycoside, penicil-
lamine, quinine and calcium-channel blockers as 
the effect of these drugs may be potentiated. As 
teratogenicity of BoNT is still unknown, it is 
advised not to use BoNT during pregnancy and 
lactation.
Cervical dystonia
BoNT injections are the first-line therapy for cer-
vical dystonia (CD). Meta-analysis of several 
double-blind, placebo-controlled trials have dem-
onstrated a beneficial effect of the BoNT type A 
(BoNT-A) versus placebo on multiple domains, 
such as dystonia severity, pain and the patient’s 
and physician’s subjective judgement. Adverse 
events are usually transient and mild. The most 
relevant side effects, of increasing frequency 
with higher doses and therefore dose-limiting, are 
neck weakness, dysphagia, dry mouth/sore throat 
and voice changes/hoarseness. Others are dose-
independent and include pain at the site of injec-
tion, malaise, upper respiratory infection and 
headache [Costa et al. 2005b].
BoNT also has proven long-term safety and 
efficacy. Several large case series have shown 
treatment efficacy up to 10 years, without long-
term adverse effects [Blackie and Lees, 1990; 
Haussermann et al. 2004]. The occurrence of a 
secondary nonresponse, likely due to antibodies 
to BoNT or other components, was rare (1–2%) 
[Kessler et al. 1999; Haussermann et al. 2004; 
Brin et al. 2008]. Also primary nonresponse is 
seen, but reports documenting its occurrence 
are sparse [Truong et al. 2005]. A comparison of 
efficacy and safety between two preparations of 
BoNT-A, (onabotulinumtoxinA [Botox®] and 
rimabotulinumtoxinA [Dysport®]), for the treat-
ment of CD showed no significant differences 
[Odergren et al. 1998; Ranoux et al. 2002; Costa 
et al. 2005a]. In 2005, incobotulinumtoxinA 
(Xeomin®), a BoNT-A drug without complexing 
proteins, was also shown to be effective and safe 
for the treatment of CD [Comella et al. 2011], 
similar to onabotulinumtoxinA [Benecke et al. 
2005; Benecke, 2009]. A direct comparison of 
these three BoNT-A preparations has not been 
done. Time will show whether the use of inco-
botulinumtoxinA is more advantageous than the 
earlier BoNT-A. When or if it will become widely 
available, if the medical insurers will reimburse 
this new variant and most importantly whether 
practitioners are willing to change the prepara-
tion they have experience with, have yet to be 
determined.
Another BoNT serotype produced by C. botuli-
num is type B (BoNT-B). A recent meta-analysis 
of three multicentre double-blind, placebo-
controlled trials demonstrated significant benefit, 
with at least 20% improvement on the total score 
of the Toronto Western Spasmodic Torticollis 
Rating Scale (TWSTRS) at week four. Subjective 
rating scales also improved. Adverse events were 
identical to BoNT-A, but they were suggested to 
be more frequent with BoNT-B. Although nonsig-
nificant, there was a larger benefit for patients 
resistant to BoNT-A compared with those still 
responding to BoNT-A [Lew et al. 1997; Brashear 
et al. 1999; Brin et al. 1999; Costa et al. 2005a]. 
Comparison of the clinical effect of BoNT-A 
and BoNT-B showed noninferiority for BoNT-B 
[Pappert and Germanson, 2008].
BoNT is thus the current gold standard for CD, 
and has also been proven to be superior to oral 
trihexyphenidyl. Prospectively, 66 CD patients 
were randomized to treatment with trihexypheni-
dyl (mean dose 16.25 mg/day) plus EMG-guided 
placebo injections (two sessions, 8 weeks apart) 
or placebo tablets plus EMG-guided BoNT-A 
injections (two sessions, 8 weeks apart), showing 
larger therapeutic effect and fewer adverse events 
for BoNT-A [Brans et al. 1996].
Blepharospasm
There are several, often uncontrolled trials of 
BoNT for the treatment of blepharospasm (BSP). 
Recently, a multicentre randomized, double-blind 
and placebo-controlled trial evaluated the effect 
of BoNT-A (Dysport, 40, 80 and 120 MU per 
eye) in 123 patients with BSP. At week four, func-
tional disability was significantly lower after treat-
ment with BoNT-A compared with placebo. The 
effect was dose-related, with continued benefit 
up to 12 weeks for all doses, and up to 16 weeks 
for 80 or 120 MU per eye. Reported side effects 
included ptosis, blurred vision, lagophthalmos, 
diplopia, increased lacrimation and aggravated 
dry eyes [Truong et al. 2008]. With regards to the 
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long-term treatment effect, a trend towards 
reduced duration of symptom relief [Gill and 
Kraft, 2010] and a necessity to increase BoNT 
dose over the years were recently mentioned 
[Cillino et al. 2010]. The different BoNT prepa-
rations are similar in terms of efficacy and adverse 
effects [Roggenkamper et al. 2006; Jankovic, 
2009; Wabbels et al. 2011].
Focal hand dystonia
The use of BoNT-A to treat writer’s cramp (WC) 
has been assessed in several placebo-controlled 
studies. Small patient numbers and different 
designs have led to inconclusive results [Yoshimura 
et al. 1992; Tsui et al. 1993; Cole et al. 1995]. In 
one of the best studies available, 39 WC patients 
were randomized to two treatment sessions with 
either BoNT-A or placebo injections. Seventy per 
cent of the BoNT-A group demonstrated an 
improvement, in contrast to 32% of the placebo 
group. Both the Writer’s Cramp Rating Scale 
(WCRS) score and writing speed significantly 
improved in favour of the BoNT-A group. Side 
effects included hand weakness, mostly mild and 
transient, and pain at the injection site. After 
1 year, 51% were still on BoNT treatment 
[Contarino et al. 2007].
Oromandibular dystonia
BoNT treatment trials in oromandibular dysto-
nia (OMD) have been small and/or open label 
[Blitzer et al. 1989; Hermanowicz and Truong, 
1991; Van Den Bergh et al. 1995; Poungvarin 
et al. 1997; Tan and Jankovic, 1999; Laskawi and 
Rohrbach, 2001]. The largest prospective open-
label study, concerning 162 patients, reported 
moderate to excellent improvement in almost 
70% of OMD patients. The jaw-closing OMD 
patients responded best. Thirty-one per cent 
reported adverse events, mostly dysphagia and 
dysarthria [Tan and Jankovic, 1999]. One single, 
placebo-controlled and double-blind study, but 
including only eight OMD-CD patients, showed 
improvement with BoNT in three patients 
[Jankovic and Orman, 1987].
Spasmodic dysphonia
For spasmodic dysphonia (SD), there is data 
from several clinical studies and meta-analyses 
[Wong et al. 1995; Brin et al. 1998; Whurr et al. 
1998; Finnegan et al. 1999; Boutsen et al. 1998; 
Watts et al. 2006, 2008; Blitzer, 2010]. One dou-
ble-blind, placebo-controlled study examined the 
effects of BoNT-A versus saline in 13 adductor 
SD patients and revealed significant effects of 
BoNT-A on voice quality, perceived voice improve-
ment and acoustic measurements [Troung et al. 
1991]. Recently, long-term effects were retro-
spectively evaluated in 55 patients, showing a 
decrease in BoNT-A dose, with increasing treat-
ment intervals and effect duration over the years 
[Birkent et al. 2009]. The reported experience 
with BoNT-B is limited. Adler and colleagues 
reported a good effect in eight of 10 patients, last-
ing up to 8 weeks [Adler et al. 2004]. In contrast 
to adductor SD reports on abductor SD are lim-
ited, showing less impressive and variable results 
[Bielamowicz et al. 2001; Woodson et al. 2006; 
Blitzer, 2010].
Other forms of focal dystonia
Axial dystonia is often part of generalized dys-
tonia or segmental dystonia, but can also present 
as an isolated form. Owing to the involvement 
of long and strong muscles, BoNT might be 
insufficient in reducing axial dystonic symp-
toms. Marked to moderate effect was, however, 
seen in several cases presenting with primary or 
tardive isolated axial dystonia without severe 
adverse effects [Mezaki et al. 1994; Comella et al. 
1998; Benecke and Dressler, 2007]. Adult-onset 
lower limb dystonia is a rare disorder in contrast 
to the more common presentation of lower limb 
dystonia in young patients, e.g. in DYT 1. It 
should therefore prompt the physician to evalu-
ate secondary causes of dystonia. Moderate to 
marked improvement with BoNT is also observed 
in patients with rare primary lower limb dysto-
nia [Duarte et al. 1995; Schneider et al. 2006a; 
Singer and Papapetropoulos, 2006; Martino et al. 
2010; Pont-Sunyer et al. 2010].
In summary, treatment with BoNT-A is an effec-
tive treatment in many of the focal dystonias, 
with good evidence in CD and BSP, and is there-
fore the first-line intervention for most of the 
focal dystonias. Although BoNT-B has only been 
thoroughly evaluated in CD, a comparable effect 
may be expected for the other focal dystonia 
subtypes but this remains largely unproven. In 
clinical practice, BoNT can also be applied in 
patients with generalized dystonia as an add on to 
other treatment interventions for selected dys-
tonic body segments.
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Oral drug therapy
Conventional drug treatment has been the cor-
nerstone in dystonia treatment for many years, 
but BoNT has taken over its position over the last 
15 to 20 years, particularly for the focal subtypes. 
Still, oral medication is widely used, particularly 
in generalized dystonia or in focal dystonias when 
there is an unsatisfactory response to BoNT 
(Table 1).
Anticholinergic agents
Anticholinergic drugs block the action of acetyl-
choline on central muscarinic receptors. Common 
adverse effects include dry mouth, blurred vision, 
constipation, urinary retention, memory loss, hal-
lucinations and behavioural changes. These side 
effects increase in frequency with age, limiting the 
use of anticholinergics in older patients [Gerretsen 
and Pollock, 2011].
In a retrospective analysis of open-label trials of 
initial treatment with anticholinergic agents, data 
from 358 primary focal and generalized dystonia 
patients were reviewed [Greene et al. 1988a]. 
A ‘good’ response, defined as a slight, moderate 
or marked improvement, was experienced by 
40–50% of patients. There was no correlation 
between a good response and distribution of dys-
tonia, sex or disease severity. Burke and colleagues 
reported an improvement up to 72% in a double-
blind, randomized crossover study using trihexy-
phenidyl versus placebo in 31 primary segmental 
or generalized dystonia patients, all younger than 
32 years. Again, distribution, aetiology and sex 
were not correlated with treatment effect [Burke 
et al. 1986]. Despite the common use in older 
adults, there is no controlled trial of trihexypheni-
dyl in older adults with dystonia.
GABA-mimetic agents
Baclofen (β-parachlorophenyl GABA) is a 
GABA-B receptor agonist that decreases the 
monosynaptic and polysynaptic reflex response 
in afferent terminal nerves and induces muscle 
relaxation. Dose-related adverse effects include 
lethargy, dizziness, gastrointestinal complaints 
and urinary frequency. In addition, psychotic 
episodes and seizures can result from abrupt 
baclofen withdrawal [De Boer et al. 2012]. In a 
retrospective analysis of open-label trials, the 
data from 108 primary dystonia patients treated 
with baclofen were reviewed [Greene et al. 1988a, 
1988b; Greene and Fahn, 1992; Greene, 1992]. 
A ‘good’ response, defined as a slight, moderate 
or marked improvement, was seen in 20% of the 
patients. BSP patients responded best (30%), in 
contrast to generalized dystonia (13%) and CD 
(11%), although these differences were not sig-
nificant. Baclofen can also be given intrathecally. 
At present, this is mainly considered in patients 
with the combined presence of spasticity and dys-
tonia (secondary to perinatal asphyxia for exam-
ple) or in status dystonicus. It has also been used 
in some cases of primary dystonia. Uncontrolled 
case series suggest that intrathecal baclofen results 
in an improvement of mainly axial and limb dys-
tonia [Diederich et al. 1997; Ford et al. 1998; 
Manji et al. 1998; Walker et al. 2000; Hou et al. 
2001; Jaffe and Nienstedt, 2001; Dykstra et al. 
2005; Teive et al. 2005; Grosso et al. 2012]. 
However, at present, there is insufficient evidence 
to support the use of intrathecal baclofen in pri-
mary dystonia or primary status dystonicus.
Benzodiazepines act by potentiating neural inhi-
bition mediated by GABA. Adverse effects of 
benzodiazepine treatment include sedation and 
confusion. Several variants have been evaluated 
in primary dystonia, mainly in CD, but none in a 
controlled setting. In the above-mentioned report 
by Greene and colleagues [Greene et al. 1988a, 
1988b], 16% of 115 patients responded well to 
clonazepam. The response rate for BSP and CD 
was 23% and 21%, respectively, while this was 
only 6% for generalized dystonia; again, these 
differences were not significant. The effect was 
not correlated with sex, aetiology, age at onset or 
severity. There are also reports of marked relief 
of dystonic symptoms after (intravenous) diaze-
pam [Ahmad and Meeran, 1979; Ziegler, 1981; 
Francis, 1983]. In the same retrospective chart 
review by Greene and colleagues, anticholiner-
gics were, however, found to be significantly 
more effective than GABA mimetics in CD and 
BSP [Greene et al. 1988a].
Dopamine-altering agents
All patients with an early onset dystonia, particu-
larly in the case of limb onset, should receive a 
trial of levodopa given the possibility of dopa-
responsive dystonia (DRD), one of the dystonia-
plus disorders. While in DRD levodopa leads to a 
considerable improvement [Steinberger et al. 
2000; Hwang et al. 2001; Nutt and Nygaard, 
2001; Schneider et al. 2006b], the effect in pri-
mary dystonia is often less impressive. Reviewing 
214 cases, 39% of generalized dystonia patients 
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Table 1. Oral drugs used in the treatment of dystonia.
Dose Adverse effects [De Boer et al. 2012]
Commonly used
Anticholinergics
Trihexyphenidyl Gradually increase to 12 mg in 4 weeks, up to 
60–100 mg q.d. [Jankovic, 2006]
Dry mouth, blurred vision, constipation, 
urinary retention, confusion, memory loss, 
hallucinations, behavioural changes
GABA-mimetics
Baclofen Gradually increase to 30 mg in 1 week, up to 
40–180 mg q.d. [Greene, 1992]
Lethargy, dizziness, gastrointestinal 
complaints, urinary frequency
Clonazepam Gradually increase in 2–4 weeks, up to 1.5–12 
mg q.d. [Greene et al. 1988a]
Drowsiness, dizziness, ataxia, confusion
Dopaminergic agents
Levodopa (DRD) Start with 100 mg levodopa + 25 mg 
decarboxylase inhibitor, increase up to 1000 
mg. When after 1 month no effect, stop and 
reconsider diagnosis DRD [Jankovic, 2006]
Dyskinesia, sleepiness, orthostatic 
hypotension, nausea, gastrointestinal 
symptoms, hallucinations, behavioural 
changes
Rarely used
Tetrabenazine Gradually increase in 7 weeks, up to 100 mg 
q.d., starting with 12.5 mg [Kenney et al. 2007]
Drowsiness, Parkinsonism, depression, 
akathisia
Apomorphine 10–50 mg continuously SC, sometimes in 
combination with levodopa / lisuride 
[Langkafel et al. 1991]
Sedation, confusion, hallucinations, skin 
irritation
Lisuride 0.4 to 5–12 mg q.d [Bassi et al. 1982; Quinn et al. 
1985]
Dyskinesia, sleepiness, orthostatic 
hypotension, nausea, gastrointestinal 
symptoms, hallucinations, behavioural 
changes
Bromocriptine 18–150 mg/day (mean 72.5 mg) [Stahl and 
Berger, 1981; Newman et al. 1985]
Nausea, vomiting, constipation, headache, 
sedation, dizziness
Clozapine Gradually increase by 12.5–25 mg q.d., up to 300 
mg q.d. [Karp et al. 1999]
Sleepiness, tachycardia, dizziness, 
constipation, granulocytopenia
Olanzapine Gradually increase by 2.5 mg q.d., up to 15 mg 
q.d. [Lin and Chang, 2004]
Sleepiness, tachycardia, dizziness, 
constipation, granulocytopenia, weight gain
Tiapride Start with 100 mg t.i.d. IV, continue with equal oral 
dose, up to 500 mg q.d. [Arlazoroff et al. 1991]
Hyperprolactinemia, sleepiness, 
dizziness, behavioural changes, headache, 
Parkinsonism
Risperidone Start with 2 mg q.d., increase daily up to 8 mg 
q.d. [Wohrle et al. 2003]
Depression, weight gain, Parkinsonism, 
headache, insomnia
Orphenadrine NA [Jacob, 1962] Dry mouth, blurred vision, constipation, 
urinary retention, confusion, memory loss, 
hallucinations, behavioural changes
Haloperidol Gradually increase by 0.5 mg q.d. to 1.5–14 mg 
q.d. [Gilbert, 1972]
Emotional deprivation, dystonia, 
Parkinsonism
Diphenidramine Start with 50 mg q.i.d., increase up to 400 mg 
q.d. [Truong et al. 1995]
Somnolence, dizziness, dry mouth, 
tachycardia, urinary retention, constipation
Mexiletine Start with 200 mg q.d., increase up to 450–1200 
mg q.d. [Ohara et al. 1998; Lucetti et al. 2000]
Dizziness, heartburn, nausea, nervousness, 
trembling, unsteadiness
Chlorzoxazone NA [Strang, 1967] Dizziness, malaise, nausea, vomiting, liver 
dysfunction
Carbamazepine Gradually increase up to 200–1200 mg q.d., 
starting with 200 mg q.d. [Geller et al. 1976]
Leukopenia, dizziness, ataxia, sleepiness, 
nausea, vomiting, skin rash
Levetiracetam Gradually increase up to 1000 mg b.i.d. / 1500 mg 
t.i.d., starting with 500 mg q.d. [Zesiewicz et al. 
2004; Sullivan et al. 2005; Yardimci et al. 2006]
Asthenia, sleepiness, ataxia, behavioural 
changes, depression, amnesia
b.i.d., twice a day; DRD, dopa-responsive dystonia; IV, intravenously; NA, not available; q.d., per day; q.i.d., four times a day; SC, subcutaneous; t.i.d., 
three times a day.
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showed marked to moderate improvement on 
levodopa, followed by CD (27%) and cranial 
dystonia (6%). No effect was found in WC 
patients [Lang, 1988].
Various dopamine-antagonist agents have been 
studied, mainly in uncontrolled trials. Given the 
potential side effects such as acute or tardive 
dystonia, their use is often discarded in dystonia 
patients. The overall picture is that of a variable 
effect. Tetrabenazine was shown to be effective in 
various types of generalized and focal dystonia in 
a small, double-blind crossover study [Jankovic, 
1982]. Recently, a retrospective chart review was 
performed on patients treated with tetrabenazine 
for a variety of hyperkinesias, including dystonia 
(n = 132), but without further details on the sub-
types of dystonia. Marked-to-moderate improve-
ment was seen in 67% and 70% after 3 and 
6 months, respectively. Common adverse effects 
included drowsiness, Parkinsonism, depression 
and akathisia [Kenney et al. 2007]. These results 
confirm earlier reports [Jankovic and Orman, 
1988; Jankovic and Beach, 1997]. In small series, 
symptomatic relief, albeit variable, has also been 
reported for phenothiazines, pimozide and 
haloperidol [Gilbert, 1972; Lang, 1988].
Clozapine is a dibenzodiazepin derivative, 
atypical antipsychotic agent that predominantly 
blocks the dopamine D4 receptor [De Boer et al. 
2012]. An open-label study in five patients with 
generalized dystonia and Meige syndrome 
revealed significant improvements upon clozap-
ine treatment, with dose-limiting adverse effects 
in one patient [Karp et al. 1999]. More recently, 
two OMD patients reported marked improve-
ment with clozapine [Hanagasi et al. 2004]. A 
third open-label report on 10 CD patients dem-
onstrated subjective improvement and a signifi-
cant decrease in the TWSTRS pain score and 
rate of clonic movements; there were however no 
significant effects for the severity and disability 
TWSTRS subscores [Burbaud et al. 1998]. In 
contrast, another open-label trial of clozapine in 
five CD patients failed to demonstrate benefit 
after 3–12 weeks of treatment [Thiel et al. 1994]. 
On top of these rather contrasting results from 
uncontrolled and small studies, the use of clozap-
ine in practice may be limited by the necessity to 
regularly monitor hematologic parameters. Other 
atypical neuroleptics, such as olanzapine, risperi-
done and tiapride, have occasionally demon-
strated marked to good improvement as well 
[Arlazoroff et al. 1991; Zuddas and Cianchetti, 
1996; Grassi et al. 2000; Wohrle et al. 2003; Lin 
and Chang, 2004].
Dopamine receptor agonists (e.g. bromocriptine, 
apomorphine, amantadine and lisuride) have also 
been tried in dystonia. In several studies reviewed 
by Lang, a variety of response rates were found: 
generalized dystonia improved with a range of 
18–50% for several dopamine receptor agonists 
(no studies on generalized dystonia and amanta-
dine), and a comparable broad range was found 
for cranial dystonia (0–62%) and CD (6–39%). 
Adverse effects led to frequent withdrawal and 
symptomatic decline was seen in nearly 25% of 
patients. The best effect was suggested to be 
obtained with apomorphine [Lang, 1988]. A small 
double-blind placebo-controlled trial in CD 
patients showed no effect for amantadine [West, 
1977]. Yet, overall the data are far from conclu-
sive. In a double-blind, placebo-controlled study 
that came out after this review and in which seven 
patients (six of whom with primary generalized 
and focal dystonia) were given apomorphine 
intravenously, five patients improved following 
injection, again suggesting that dopamine ago-
nists could be an effective treatment in various 
subtypes of dystonia, but more work is needed 
[Langkafel et al. 1991].
Many patients with dystonia need a combination 
of several drugs and other treatments to obtain 
sufficient symptomatic relief. Marsden and col-
leagues proposed a triple therapy, known as the 
‘Marsden cocktail’, consisting of a dopamine 
antagonist (tetrabenazine), a dopamine-blocking 
drug (pimozide) and, in patients with severe dys-
tonia, the addition of an anticholinergic agent. 
Seventy-five per cent of the adults with severe axial 
dystonia experienced substantial improvement 
from this drug combination [Marsden et al. 1984].
Various other oral pharmacological agents, such as 
carbamazepine, levetiracetam, orphenadrine, chlo-
rzoxazone, diphenidramine and mexiletine have 
been reported to give some symptomatic relief in 
dystonia patients, but these observations should be 
labelled as anecdotal [Jacob, 1962; Strang, 1967; 
Geller et al. 1976; Ten Houten et al. 1984; Truong 
et al. 1995; Ohara et al. 1998; Lucetti et al. 2000; 
Zesiewicz et al. 2004; Sullivan et al. 2005; Yardimci 
et al. 2006; Hering et al. 2007].
In summary, various oral drugs are being used 
in the treatment of primary dystonia. There is 
a remarkable absence of sufficiently large, 
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randomized controlled trials (RCTs). Most 
data come from large, retrospective case series 
or medium-sized, prospective open-label stud-
ies. As sound evidence for most of the oral 
pharmacological agents is lacking, there is no 
consensus about this line of treatment. At pre-
sent, anticholinergics seem to be the most 
promising group, followed by the GABA 
mimetics. The order in which oral drugs should 
be started, the maximum dose at which they 
can or should be given, and when or how to 
combine different drugs are still determined by 
the practitioner’s personal experience. Table 2 
indicates how we use the drugs discussed above 
per dystonia subtype.
Surgical treatment
For many patients with generalized dystonia, and 
also for some with focal dystonia, all pharmaco-
logical options outlined above offer insufficient 
relief. Surgical treatment may then be considered. 
Surgery in dystonia has a long history and over 
the years several procedures have been performed: 
selective peripheral denervation (typically in CD, 
Bertrand procedure), myectomy (SP and BSP) 
and stereotactic lesioning of the basal ganglia or 
thalamus. The current surgical treatment of 
choice in most cases, however, is deep brain 
stimulation (DBS).
Deep brain stimulation
DBS is an established treatment of Parkinson’s 
disease and essential tremor. DBS alters neu-
ronal discharge or axonal propagation (or both) 
in the target structure that is stimulated. The 
exact mechanism by which this effect occurs, is 
still unclear. Advantages over stereotactic surgery 
are adaptability of stimulation and reversibility in 
case of adverse effects [Katayama et al. 2003]. 
Kupsch and colleagues reported a randomized 
multicentre double-blind series of 40 patients 
with primary segmental dystonia and primary 
generalized dystonia using bilateral pallidal DBS 
or sham stimulation. After 3 months, patients 
receiving DBS showed almost 40% improvement 
in BFMDRS movement and disability scores, 
increasing further after 6 months [Kupsch et al. 
2006]. A second randomized, double-blind mul-
ticentre trial of bilateral pallidal DBS in 22 pri-
mary generalized dystonia patients disclosed 
similar effects [Vidailhet et al. 2005]. There is 
limited data on the (very) long-term effects, 
though clinical improvement is seen up to 
6 years [Vidailhet et al. 2007; Loher et al. 2008]. 
Longer follow-up data will become available over 
the next few years.
Patients with focal rather than generalized dysto-
nia appear to benefit from DBS as well. Most 
publications concern bilateral pallidal stimulation 
Table 2. Advised treatment options per dystonia subtype.
First-line treatment Add-on treatment Treatment in 
refractory cases
Cervical dystonia BoNT Trihexyphenidyl Tetrabenazine
 Baclofen Pallidal DBS
 Clonazepam Selective peripheral 
denervation
Blepharospasm BoNT Baclofen DBS
 Clonazepam Myectomy
Oromandibular dystonia BoNT Baclofen  
 Clonazepam  
 Tetrabenazine  
Focal hand dystonia BoNT  
Spasmodic dystonia BoNT Myectomy
Generalized dystonia Trihexyphenidyl BoNT Pallidal DBS
 Baclofen
Clonazepam
Tetrabenazine / 
Neuroleptics
 Intrathecal baclofen
BoNT, botulinum neurotoxin; DBS, deep brain stimulation.
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in CD. One prospective, single-blinded multicentre 
trial has been reported, in which 10 patients with 
chronic and therapy-resistant CD were evaluated. 
The TWSTRS severity score improved by 44% 
after 12 months, and TWSTRS disability and pain 
subscores by 64% and 65%, respectively. Also 
general health, physical functioning and depres-
sion improved; only mild or transient adverse effects 
were seen, comparable to generalized dystonia 
[Kiss et al. 2007]. A long-term effect up to 3 years 
after surgery has been reported in smaller series of 
CD patients [Bittar et al. 2005; Hung et al. 2007; 
Huh et al. 2010; Pahapill and O’Connell, 2010].
Patients with cranio-cervical dystonia, e.g. Meige 
syndrome, have also been treated with DBS. 
Twelve patients with Meige syndrome were evalu-
ated retrospectively up to 78 months, reporting a 
mean BFMDRS improvement of 45% at short-
term follow up and 53% at long-term follow up, 
without clear differences between eye, mouth or 
speech subscores [Reese et al. 2011]. Comparable 
results were found in other series, also reporting 
reversible stimulation-induced bradykinesia in 
previously nondystonic limbs after prolonged pal-
lidal DBS [Ostrem et al. 2007; Ghang et al. 2010].
There are limited data with regard to DBS target-
ing other sites than the internal pallidum. Several 
series describe DBS of the subthalamic nucleus 
(STN) in dystonia [Mundinger, 1977; Andy, 
1983; Kleiner-Fisman et al. 2007; Moll et al. 
2008; Cho et al. 2009; Allert et al. 2010; Pahapill 
and O’Connell, 2010]. A prospective, single-
blinded pilot study reported on nine CD patients 
with STN-DBS, improving 37% on the TWSTRS 
total score at 12 months. Quality of life measures 
also improved and STN-DBS caused no cogni-
tive side effects or Parkinsonism [Ostrem et al. 
2011]. The posterior part of the ventrolateral tha-
lamic nucleus has also been targeted [Vercueil 
et al. 2001]. Two out of a series of three patients 
with primary generalized dystonia experienced a 
mild-to-moderate improvement of limb dystonia, 
whereas axial symptoms remained unchanged.
DBS-related adverse effects can be caused by the 
surgical procedure itself, the implanted hardware 
or brain stimulation. Speech abnormalities, 
referred to as dysarthria, dysphonia or stuttering, 
are reported frequently. Other side effects include 
perioral tingling, poor coordination and slowness, 
akinesia and bradykinesia, gait difficulties, pares-
thesias, abnormalities of posture, laughter and 
lethargy [Tagliati et al. 2011]. Two suicides have 
been reported in patients with dystonia after 
DBS, but both patients had symptoms of depres-
sion before DBS [Foncke et al. 2006]. We are cur-
rently left uninformed about the potential 
long-term adverse effects of DBS in dystonia.
Several factors may contribute to a favourable 
outcome of DBS in dystonia. Several retrospec-
tive studies identified young age and short disease 
duration as positive predictors [Coubes et al. 
2004; Alterman and Snyder, 2007; Vasques et al. 
2009; Andrews et al. 2010; Isaias et al. 2011]. The 
debate on the influence of disease duration in 
generalized dystonia is, however, ongoing, as well 
on the predictive factors in CD patients [Hung 
et al. 2007; Valldeoriola et al. 2010]. Previously, 
there were reasons to believe that a mutation in 
the DYT1 gene underlying generalized dystonia 
also withheld a more favourable response to DBS 
[Borggraefe et al. 2008], but this has not been 
replicated by others [Coubes et al. 2004; Vidailhet 
et al. 2005, 2007; Kupsch et al. 2006].
Despite the good evidence to support DBS in 
therapy-resistant dystonia, other surgical proce-
dures are still used. These procedures (e.g. thala-
motomy in CD and WC; peripheral denervation 
in CD) seem to be performed most in Asian 
countries where BoNT treatment is often not 
reimbursed by the medical insurers. Myectomy is 
still regularly used in BSP when patients are 
refractory to BoNT.
Peripheral surgical denervation in CD
Peripheral surgical denervation gives similar 
improvement in objective and subjective ratings 
as pallidal DBS [Huh et al. 2010]. There are dif-
ferent peripheral denervation procedures: poste-
rior ramisectomy [Bertrand et al. 1978] with or 
without myotomy; anterior cervical rhizotomy; 
and microvascular decompression of the spinal 
accessory nerve, are used for focal and segmental 
dystonias. A direct comparison of these methods 
is lacking. Moderate to excellent improvement in 
head position and pain was reported in patients 
treated with posterior ramisectomy, even in the 
long term. Persistent C2-distributed dysesthesias, 
shoulder girdle weakness and muscle reinnerva-
tion-related pain are common adverse effects 
[Munchau et al. 2001; Cohen-Gadol et al. 2003]. 
Recently, a new method of peripheral denervation 
was applied, obtaining similar benefit but with 
less sensory disturbances [Taira and Hori, 2003a]. 
Results of intradural procedures are highly 
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variable, ranging from 60% to 90% postoperative 
improvement [Hamby and Schiffer, 1969, 1970; 
Arseni and Maretsis, 1971; Fabinyi and Dutton, 
1980; Colbassani and Wood, 1986; Speelman 
et al. 1987; Gauthier et al. 1988; Hernesniemi and 
Keranen, 1990]. The two main concerns are the 
sustainment of the effect and the adverse events. 
The question is which CD patients to consider 
suitable for this type of surgery. The direction of 
CD seems an important element here. The risk-
to-benefit ratio is perhaps poorest in antecollis, 
and one would at present consider DBS in 
such patients first (see above). A crucial factor 
here is the experience of the surgical team and 
only a couple of centres in the world meet this 
criterion.
Myectomy
Surgical treatment can be considered in BoNT-
unresponsive BSP. In recent years, various forms 
of myectomy or frontal suspension have been 
reported on [Nicoletti et al. 2009; Patil and Foss, 
2009]. Retrospective studies report marked 
improvement or resolution of BSP and increased 
effect of BoNT with myectomy or single frontal 
suspension, with long-term benefit [Chapman 
et al. 1999; Grivet et al. 2005; Wabbels and 
Roggenkamper, 2007; Georgescu et al. 2008]. 
Also in SD, different types of myectomy of the 
thyroarytenoid muscle are performed [Remacle 
et al. 2005; Tsuji et al. 2006; Kim et al. 2008; 
Nakamura et al. 2008]. The therapeutic effect and 
adverse events depend on the type of surgery. 
Limited myectomy produces less benefit with 
more frequent symptom recurrence after 6 
months necessitating BoNT, while complete 
myectomy or myectomy with neurectomy leads to 
a longer lasting improvement, but with adverse 
breathing impairment. Facial nerve lysis in BSP 
and recurrent laryngeal nerve section in SD have 
been abandoned since the arrival and efficacy of 
BoNT [Ludlow, 2009].
Stereotactic surgery
Thalamotomies have been performed in patients 
with generalized dystonia and CD, using the Voa, 
Vop, Vim, subthalamic region, centromedian 
nucleus and pulvinar as targets [Hassler and 
Dieckmann, 1970; Krayenbuhl and Siegfried, 
1972; Mundinger et al. 1972; Andrew et al. 1974, 
1983; Gros et al. 1976; Cardoso et al. 1995; Imer 
et al. 2005]. Results have been variable, with 
improvement rates between 15% to 25% of 
patients; rates were highest for those with primary 
dystonia. Serious complications were found in a 
quarter of those who received surgery [Cooper, 
1976; Tasker et al. 1988]. More recently, thalam-
otomy was performed in 12 patients with focal 
hand dystonia (FHD; WC and musician’s cramp), 
reporting significant improvement of the WCRS 
directly after surgery. Two patients relapsed 
5 months after surgery [Taira and Hori, 2003b]. 
With regard to pallidotomy, only smaller case 
series of anterior or posteroventral pallidotomy in 
primary (generalized) dystonia patients have been 
published with highly variable results [Iacono 
et al. 1996; Lozano et al. 1997; Ondo et al. 1998]. 
Frequently reported adverse effects included 
speech problems and cognitive deficits [Hariz 
et al. 2011]. Appreciating the limitation caused by 
methodological differences between the two sur-
gical groups, pallidotomy exhibits significantly 
better long-term outcomes than thalamotomy 
[Yoshor et al. 2001].
A direct comparison of DBS versus stereotactic 
surgery has not been done, and even an indirect 
comparison is difficult as no randomized, pla-
cebo-controlled, double-blind trials for the latter 
exist. Despite the preferable use of DBS in pre-
sent practice, one could question the current 
place of stereotactic surgery. It can be argued that 
the effectiveness of stereotactic surgery is underes-
timated as concerning literature dates from a 
period of surgical development. On the other 
hand, results may be overestimated due to the 
absence of RCTs. Second, stereotactic surgery is 
free of limitations concerning hardware and pro-
gramming issues as seen with DBS, possibly lead-
ing to lower costs. Overall, the use of stereotactic 
surgery may be up for debate, especially with the 
arrival of studies on modern stereotactic tech-
niques [Gross, 2008].
In summary, pallidal DBS is proven to be effica-
cious in primary generalized dystonia. Evidence 
also suggests beneficial effects for CD and possi-
bly for cranial dystonia. The long-term effects and 
side effects of pallidal DBS, and proof of effect of 
DBS in other types of dystonia and perhaps other 
stimulation sites have to be addressed more thor-
oughly in future studies. Given the level of evi-
dence, current experience and assumed lower rate 
of adverse events, DBS is at present the preferred 
technique above stereotactic surgery. Also, selec-
tive peripheral denervation and myectomy may, 
when performed in experienced centres, be effec-
tive substitutes for DBS for some focal subtypes 
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that respond insufficiently to BoNT and oral 
pharmacotherapy.
Noninvasive neurostimulation
Despite the limited understanding of the patho-
physiology of primary dystonia, three mecha-
nisms are thought to be fundamental contributors. 
A loss of inhibition on several levels of the central 
nervous system has been demonstrated, leading 
to unnecessary contractions of more muscles 
than required [Hallett, 2011]. Other evidence 
suggests that somatosensory processing and sen-
sorimotor integration are altered [Hallett, 2011], 
possibly as a consequence of underlying maladap-
tive synaptic plasticity [Quartarone et al. 2008]. 
Alteration of these abnormal activity patterns 
may serve as new therapeutic targets for noninva-
sive neurostimulation. Although still in the exper-
imental stage, transcranial magnetic stimulation 
(TMS) and transcranial direct current stimula-
tion (tDCS) are mentioned here.
Transcranial magnetic stimulation
TMS is a noninvasive method to depolarize or 
hyperpolarize neurons. It uses electromagnetic 
induction to induce weak electric currents using a 
rapidly changing magnetic field. This can cause 
activity in targeted (and remote) areas of the brain, 
allowing the functioning and interconnections of 
the brain to be studied or temporarily altered.
To the best of the authors’ knowledge, only nine 
reports on TMS exist, mainly all on FHD patients 
[Siebner et al. 1999a, 1999b; Bhidayasiri and 
Bronstein, 2005; Murase et al. 2005; Allam et al. 
2007; Borich et al. 2009; Havrankova et al. 2010; 
Huang et al. 2010; Kranz et al. 2010]. Testing 
low-intensity repetitive TMS (rTMS) in separate 
sessions over the primary motor cortex, supple-
mentary motor area, and dorsal premotor cortex 
(PMd) in nine dystonic WC patients, Murase and 
colleagues found that only PMd stimulation 
improved handwriting. The duration of the effect 
was left unmentioned. Patients received rTMS 
three times, each session over a different site with 
an interval of 1 week [Murase et al. 2005]. Borich 
and colleagues reported a similar improvement 
after PMd stimulation lasting for 5–10 days in a 
small part of the study population [Borich et al. 
2009]. In contrast, TMS over the primary motor 
cortex in 16 WC patients demonstrated no sig-
nificant effect [Siebner et al. 1999a, 1999b]. 
Interestingly, a case study with rTMS over the 
left PMd in neck and limb dystonia showed 
improvement of neck but not of limb symptoms 
[Allam et al. 2007]. Others have tried to modu-
late sensory input. In a single blinded, partial 
crossover randomized trial, 11 WC patients were 
treated with rTMS over the contralateral primary 
sensory cortex for 5 consecutive days. The largest 
effect was found in an objective handwriting 
measure (31%) directly after the treatment, last-
ing at least for 3 weeks [Havrankova et al. 2010]. 
TMS over the anterior cingulate cortex in BSP 
(12 patients) resulted also in subjective and 
objective improvement, scored as the percentage 
of improvement in blink frequency, time of eye 
closure and the number of sustained blinks. 
Effects lasted at least until 3 hours after rTMS 
[Kranz et al. 2010].
Transcranial direct current stimulation
tDCS works by sending constant, low direct cur-
rent through two surface electrodes. When these 
electrodes are placed in the region of interest, the 
current induces intracerebral current flow alter-
ing neuronal excitability and leading to alteration 
of brain function. Four reports on tDCS were 
found, all reporting on FHD (especially musi-
cian’s cramp). In a randomized, double-blind, 
sham-controlled study, 12 unilateral dystonic WC 
patients were investigated. Cathodal or placebo 
stimulation of the contralateral motor cortex 
was used in three sessions within 1 week without 
clinical benefit or restoration of handwriting kin-
ematics and cortical inhibition. Remarkably, sub-
jective improvement was seen in the sham group 
[Benninger et al. 2011]. A placebo-controlled, 
double-blinded study on professional guitarists 
with musician’s dystonia using cathodal tDCS 
over the primary motor cortex contralateral to the 
affected hand, did not improve fine motor con-
trol. However, in one guitarist, suffering from arm 
dystonia (the other guitarists suffered from hand 
dystonia), motor control did improve [Buttkus 
et al. 2010b]. A beneficial effect of tDCS as add 
on with sensorimotor retraining in nine pianists 
could also not be established [Buttkus et al. 2010a, 
2010b]. Despite the absence of improvement after 
single-session tDCS, future stimulation protocols 
have to be optimized and may reveal a more 
favourable effect in the future.
In summary, as more insight in the pathophysiol-
ogy of primary dystonia is gained, noninvasive neu-
rostimulation may be a promising new treatment 
option. Future studies have to be performed to 
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identify the best cerebral targets and stimulation 
protocols that will lead to lasting and objective 
improvement of dystonic symptoms. This might be 
translated to a more continuous, yet invasive form 
of cortical stimulation. Already (pre)motor cortical 
stimulation is being piloted in primary and second-
ary dystonia patients with moderate effect [Romito 
et al. 2007; Messina et al. 2011; Lalli et al. 2012].
Treatment of common complications
Pain
With a prevalence ranging between 67% and 75%, 
pain is one of the most frequently forwarded 
symptoms in dystonia. It does not invariably cor-
relates with disease severity. Often pain sensation 
is aggravated by additional low mood [Kuyper 
et al. 2011; Stamelou et al. 2011]. Other than pain 
reduction by BoNT treatment [Costa et al. 2005a], 
no other pharmacological agents have been stud-
ied for their specific effect on pain in dystonia. 
Routinely, traditional analgesics are often given. 
Reduction of painful dystonic spasms with BoNT 
and addressing aggravating comorbidities are thus 
essential in the treatment of dystonic pain.
Mood
Depression is a highly prevalent comorbidity in 
dystonia, either secondary to dystonic symptoms 
and its chronicity or as a primary disease feature 
perhaps [Kuyper et al. 2011; Stamelou et al. 2011]. 
In addition to the well-known treatment with anti-
depressants or cognitive therapy [Cipriani et al. 
2009; Jakobsen et al. 2011a, 2011b], depressive 
complaints may be indirectly and partly reduced 
by treatment aimed at reducing dystonia severity. 
Treatment with BoNT is suggested to relief low 
mood in several subtypes of primary dystonia and 
also DBS can lead to mild improvement of depres-
sion [Hariz et al. 2011; Jahanshahi et al. 2011; 
Jahanshahi and Marsden, 1992; Ochudlo et al. 
2007; Slawek et al. 2007]. In contrast, worsening 
of a mood disorder and even suicide have also 
been reported after DBS. As dystonic symptoms 
were evidently reduced by adequate therapy in 
these cases, severity of dystonia does not necessar-
ily correlate with symptoms of depression [Foncke 
et al. 2006; Kuyper et al. 2011; Ostrem et al. 2011].
Orthopaedic and neurological complaints
Other common complications in mainly CD 
patients and in patients with generalized dystonia 
are orthopaedic and neurological complications. 
These include premature (cervical) spine degen-
eration, spondylosis, disc herniation, vertebral 
subluxations and fractures, radiculopathies and 
myelopathy. Negative predictors are generaliza-
tion of dystonic symptoms, age and disease sever-
ity. In addition to the premature occurrence of 
degenerative spinal complications [Konrad et al. 
2004; Guettard et al. 2012], the spine is affected 
at higher cervical levels (C2–C5) in dystonia in 
contrast to the middle and lower cervical spine 
involvement (C5–C7) in aging [Loher et al. 2006]. 
There is no consensus about the optimal surgical 
procedure for these spinal complications caused 
by dystonia. Several types of spinal surgery 
(laminectomy, anterior(–posterior) decompres-
sion with intercorporal fusion) with or without 
immobilization (halo-vest, hard or soft collars 
depending on the type of spinal surgery) may 
ameliorate symptoms. One has to be alert to sec-
ondary problems as spinal instability, pseudar-
throsis and adjacent-level disease [Konrad et al. 
2004; Wong et al. 2005; Loher et al. 2006]. Spinal 
surgery in dystonia is further complicated by con-
tinuous mechanical forces due to dystonic posture, 
which can be alleviated by preoperative and post-
operative use of BoNT or DBS [Traynelis et al. 
1992; Adler et al. 1996; Racette et al. 1998; Krauss 
et al. 2002; Tonomura et al. 2007]. Also scoliosis 
or contractures of ankle, wrist or hand are com-
monly seen. Despite limited evidence, standard 
physiotherapy, BoNT or serial casting may be use-
ful in reducing symptoms of the latter. Evaluation 
of the treatment of scoliosis in dystonia is lacking 
[Singer et al. 2004; Olver et al. 2010].
Conclusion
We have here provided an overview of the medical 
treatment options in primary dystonia. A sum-
mary of the advised treatments options per dysto-
nia subtype is given in Table 2. It is clear that only 
some of the medical treatment options have been 
evaluated through properly conducted studies and 
thus that levels of evidence for many interventions 
are low. Choosing the best treatment strategy, 
especially when the dystonic symptoms are refrac-
tory to first-line treatment, is thus often based on 
the physician’s opinion and experience, and our 
Table 2 should also be regarded as such. In addi-
tion to the treatment of the dystonia, attention to 
and treatment of frequently seen nonmotor com-
plications, such as pain and depression, is crucial 
[Stamelou et al. 2011], as well as of secondary 
orthopaedic and neurological complications, such 
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as those inflicted by cervical spinal degeneration. 
A systematic review of the allied healthcare 
interventions that can be considered in dystonia 
patients has recently been published [Delnooz 
et al. 2009]. Further understanding of the patho-
physiology of dystonia will lead to the develop-
ment of more mechanism-based interventions, of 
which repetitive TMS over the premotor cortex in 
WC is a preliminary example.
Search
For the literature search, we focused on primary 
dystonia. Therapies we included were pharma-
cological therapies, peripheral denervation, 
myectomy, stereotactic surgery and (noninvasive) 
neurostimulation. Studies could be RCTs, patient–
control studies (retrospective and prospective) 
and case series or single case reports. When 
going through the various studies, only those that 
included a report on clinical outcome, either objec-
tively (rating scales) or subjectively, were selected. 
We searched the database from 1950 to February 
2012; only English publications were selected. 
PubMed and The Cochrane Library were searched 
in February 2012. The medical subject heading 
(MeSH) and free texts search terms used to 
identify relevant reports were ‘dystonia’ OR ‘dys-
tonic disorder’ AND ‘pharmacological therapy’ 
OR ‘anticholinergics’ OR ‘baclofen’ OR ‘benzodi-
azepines’ OR ‘tetrabenazine’ OR ‘dopamine’ OR 
‘clozapine’ OR ‘botulinum toxin’ OR ‘deep brain 
stimulation’ OR ‘thalamotomy’ OR ‘pallidotomy’ 
OR ‘stereotactic surgery’ OR ‘transcranial magnetic 
stimulation’ OR ‘transcranial direct current stimu-
lation’ OR ‘myectomy’ OR ‘peripheral denervation’ 
OR ‘motor cortex stimulation’. Furthermore, cross-
references were evaluated and the authors also 
searched their personal literature database.
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